Abstract
Obesity is a major risk factor for COVID-19 severity; however, the underlying mechanism is not fully understood. Considering that obesity influences the human plasma proteome, we sought to identify circulating proteins mediating the effects of obesity on COVID-19 severity. We first screened 4,907 plasma proteins to identify proteins influenced by body mass index (BMI) using Mendelian randomization (MR). This yielded 1,216 proteins, whose effects on COVID-19 severity were assessed, again using MR. This two-step approach identified nephronectin (NPNT), for which a one standard deviation increase was associated with severe COVID-19 (odds ratio = 1.71, 95% CI: 1.45–2.02, P = 1.63 × 10-10). Colocalization analyses indicated that an NPNT splice isoform drove this effect. Overall, NPNT mediates 3.7% of the total effect of BMI on severe COVID-19. Finally, we found that decreasing body fat mass and increasing fat-free mass can lower NPNT levels and thus may improve COVID-19 outcomes. These findings provide actionable insights into how obesity influences COVID-19 severity.
Competing Interest Statement
JBR's institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline, and Biogen for projects unrelated to this research. He is the CEO of 5 Prime Sciences (www.5primesciences.com), which provides research services for biotech, pharma, and venture capital companies for projects unrelated to this research. T.L., V.F., and Y.F are employees of 5 Prime Sciences.
Funding Statement
The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511, 100558, 169303), the McGill Interdisciplinary Initiative in Infection and Immunity (MI4), the Lady Davis Institute of the Jewish General Hospital, the Jewish General Hospital Foundation, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK, Genome Québec, the Public Health Agency of Canada, McGill University, Cancer Research UK [grant number C18281/A29019] and the Fonds de Recherche Québec Santé (FRQS). JBR is supported by an FRQS Mérite Clinical Research Scholarship. Support from Calcul Québec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. S.Y. is supported by the Japan Society for the Promotion of Science. T.L. has been supported by a Vanier Canada Graduate Scholarship, an FRQS doctoral training fellowship, and a McGill University Faculty of Medicine Studentship. These funding agencies above had no role in the design, implementation, or interpretation of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For summary-level data, all contributing cohorts obtained ethical approval from their intuitional ethics review boards. The contributing cohorts include: UK Biobank, GIANT consortium, deCODE study, FENLAND study, AGES Reykjavik study, INTERVAL study, COVID-19 Host Genetics Initiative, and BQC19. For individual-level data in BQC19, BQC19 received ethical approval from the Jewish General Hospital research ethics board (2020-2137) and the Centre hospitalier de l’Université de Montréal institutional ethics board (MP-02-2020-8929, 19.389).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
GWAS summary statistics for each trait is available as follows: Body mass index (https://portals.broadinstitute.org/collaboration/giant/), Plasma proteome from the deCODE study (https://www.decode.com/summarydata/), COVID-19 outcomes (https://www.covid19hg.org/results/r7/), GTEx Portal V8 (https://gtexportal.org/home/datasets/). Plasma proteome from BQC19 (https://www.mcgill.ca/genepi/mcg-covid-19-biobank). Access to the data of BQC19 can be obtained upon approval of requests. Cis-pQTLs of each study are available in the corresponding publications' supplementary materials26-28. Body fat mass and fat-free mass GWASs are available at IEU OpenGWAS project with Accession ID of ukb-b-19393 and ukb-b-13354, respectively (https://gwas.mrcieu.ac.uk/). Single-cell RNA-sequencing data of COVID-19 lung autopsy samples are available at the Single Cell Portal under the Accession ID of SCP1052 (https://singlecell.broadinstitute.org/single_cell/). CADD-scores v.1.6 can be accessed at https://cadd.gs.washington.edu/score. Genotype data from 1000G genomes project is available at https://www.internationalgenome.org/data.
